Patents by Inventor Bruce D. Dorsey

Bruce D. Dorsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES
    Publication number: 20180179159
    Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein.
    Type: Application
    Filed: February 23, 2018
    Publication date: June 28, 2018
    Inventors: Nadine C. Becknell, Reddeppa Reddy Dandu, Bruce D. Dorsey, Dimitar B. Gotchev, Robert L. Hudkins, Linda Weinberg, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline inhibitors of Atypical protein Kinase C
    Patent number: 9914730
    Abstract: The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C (“aPKC”) inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 13, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J Dugan, Katherine M. Fowler, Robert L Hudkins, Eugen F. Mesaros, Nathaniel J. T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
  • 1,4-substituted piperidine derivatives
    Patent number: 9902696
    Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: February 27, 2018
    Assignee: Cephalon, Inc.
    Inventors: Nadine C. Becknell, Reddeppa Reddy Dandu, Bruce D. Dorsey, Dimitar B. Gotchev, Robert L. Hudkins, Linda Weinberg, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 9896446
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 20, 2018
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R. A. Roffey, Nathaniel J. T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C
    Publication number: 20170158706
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: January 26, 2017
    Publication date: June 8, 2017
    Applicant: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R.A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 9604994
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: March 28, 2017
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D Dorsey, Keith S. Learn, Emma L. Morris, Gregory R Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS
    Publication number: 20170027948
    Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 2, 2017
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Gregory R. Ott
  • Substituted Aromatic Sulfur Compounds and Methods of Their Use
    Publication number: 20170029367
    Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: Bruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak
  • 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES
    Publication number: 20160368874
    Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 22, 2016
    Inventors: Nadine C. Becknell, Reddeppa Reddy Dandu, Bruce D. Dorsey, Dimitar B. Gotchev, Robert L. Hudkins, Linda Weinberg, Craig A. Zificsak, Allison L. Zulli
  • Macrocyclic compounds as ALK, FAK and JAK2 inhibitors
    Patent number: 9487529
    Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: November 8, 2016
    Assignee: Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Gregory R. Ott
  • Substituted aromatic sulfur compounds and methods of their use
    Patent number: 9475766
    Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: October 25, 2016
    Assignees: Cephalon, Inc., University of Utah Research Foundation, University of Hawaii
    Inventors: Bruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20160102094
    Abstract: The present application provides a compound of formula (1) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Applicants: IGNYTA, INC., Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R.A. Roffey, Nathaneil J.T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • Azaquinazoline Inhibitors Of Atypical Protein Kinase C
    Publication number: 20150274720
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Application
    Filed: March 25, 2015
    Publication date: October 1, 2015
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel JT Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R.A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • Thienopyrimidine Inhibitors of Atypical Protein Kinase C
    Publication number: 20140323435
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 30, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R.A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20140113882
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 24, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J.T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
  • Macrocyclic Compounds as ALK, FAK and JAK2 Inhibitors
    Publication number: 20140031351
    Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
    Type: Application
    Filed: September 13, 2013
    Publication date: January 30, 2014
    Applicant: Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Gregory R. Ott
  • Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
    Patent number: 8633173
    Abstract: This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: January 21, 2014
    Assignee: Cephalon, Inc
    Inventors: Matthew A. Curry, Bruce D. Dorsey, Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros, Karen L. Milkiewicz
  • Substituted Aromatic Sulfur Compounds and Methods of Their Use
    Publication number: 20140005175
    Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
    Type: Application
    Filed: August 26, 2013
    Publication date: January 2, 2014
    Applicants: Cephalon, Inc., University of Utah Research Foundation, University of Hawaii
    Inventors: Bruce D. Dorsey, Scott K. Kuwada, Jay P. Theroff, Craig A. Zificsak
  • Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives
    Publication number: 20130296312
    Abstract: This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.
    Type: Application
    Filed: June 18, 2013
    Publication date: November 7, 2013
    Inventors: Matthew A. Curry, Bruce D. Dorsey, Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros, Karen L. Milkiewicz
  • Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
    Patent number: 8552186
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: October 8, 2013
    Assignee: Cephalon, Inc.
    Inventors: Gulzar Ahmed, Henry J. Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce D. Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph Lisko, Rong-qiang Liu, Eugen F. Mesaros, Karen L. Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak